Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Evaluation of Optina Retina Scans to Detect the Likeley Cerebral Amyloid Status (CAS) as Determined by Prospective PET Imaging

Authors not listed

Optina Diagnostics Inc. · 2022

Abstract

This is a non-randomized, non-treatment, observational study designed to discover correlations between retinal imaging and amyloid PET imaging. Subjects will be recruited to the clinical cohort from referring physicians. Subjects may be participants from existing studies and clinical practices

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-26 MST

Cite this

APA
Anonymous. (2022). Evaluation of Optina Retina Scans to Detect the Likeley Cerebral Amyloid Status (CAS) as Determined by Prospective PET Imaging. <em>Optina Diagnostics Inc.</em>. https://clinicaltrials.gov/study/NCT05215782
Vancouver
Anonymous. Evaluation of Optina Retina Scans to Detect the Likeley Cerebral Amyloid Status (CAS) as Determined by Prospective PET Imaging. Optina Diagnostics Inc.. 2022.
BibTeX
@misc{anon2022Evalua, title = {Evaluation of Optina Retina Scans to Detect the Likeley Cerebral Amyloid Status (CAS) as Determined by Prospective PET Imaging}, author = {Anonymous}, journal = {Optina Diagnostics Inc.}, year = {2022}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings